4.32MMarket Cap-330P/E (TTM)
0.5336High0.3900Low2.41MVolume0.4820Open0.5351Pre Close1.05MTurnover50.58%Turnover RatioLossP/E (Static)8.65MShares1.120052wk High1.96P/B2.38MFloat Cap0.291452wk Low--Dividend TTM4.76MShs Float115.2000Historical High--Div YieldTTM26.83%Amplitude0.2914Historical Low0.4380Avg Price1Lot Size
Exicure Stock Forum
BPC UPDATE 02/06/2024 ET
Pre-Market Updates
Exicure Inc (NASDAQ: XCUR) announced that it has licensed some of its patents to Bluejay Thearapeutics for advanced clinical development on the treatment of hepatitis. Bluejay will receive an exclusive license in the field of hepatitis to all of Exicure’s relevant patents. Bluejay paid Exicure an initial small, one-time payment after the execution of the deal.
$DMK Pharmaceuticals(DMK.US)$ $NanoString Technologies(NSTG.US)$ $Phunware(PHUN.US)$ $Exicure(XCUR.US)$ $Gorilla Technology(GRRR.US)$
📊⚡️📊
$Gorilla Technology(GRRR.US)$ $Exicure(XCUR.US)$ $Volcon(VLCN.US)$ $Biofrontera(BFRI.US)$ $Yield10 Bioscience(YTEN.US)$ $Atara Biotherapeutics(ATRA.US)$
📊⚡️📊
5 MINUTES AGO, 4:01 PM EST
VIA BUSINESSWIRE
No comment yet